Recombinant adeno-associated viruses (AAVs) are robust and versatile tools for in vivo gene 32 delivery. Natural and designer capsid variations in AAVs allow for targeted gene delivery to 33 specific cell types. Low immunogenicity and lack of pathogenesis also add to the popularity of 34 this virus as an innocuous gene delivery vector for gene therapy. AAVs are routinely used to 35 express recombinases, sensors, detectors, CRISPR-Cas9 components, or to simply overexpress a 36 gene of interest for functional studies. High production demand has given rise to multiple platforms 37 for production and purification of AAVs. However, most platforms rely heavily on large amounts 38 of starting material and multiple purification steps to produce highly purified viral particles. Often, 39 researchers require several small-scale purified AAVs. Here, we describe a simple and efficient 40 technique for purification of recombinant AAVs from small amounts of starting material in a two-41 step purification method. In this method, AAVs are released into the packaging cell medium using 42 high salt concentration and pelleted by ultracentrifugation to remove soluble impurities. Then, the 43 resuspended pellet is purified using a protein spin-concentrator. The two-step purification 44 consisting of ultracentrifugation and spin-concentration eliminates the need for fraction collection 45 and the time-consuming evaluation of individual fractionated aliquots for titer and purity. In this 46 method, the resulting AAV preparations are comparable in titer and purity to commercially 47 49 50 51
available samples. This simplified process can be used to rapidly generate highly purified AAV 48 particles in small scale, thereby saving resources.
Introduction

54
Recombinant adeno-associated viruses (rAAVs, referred to as AAVs in this manuscript) are 55 replication-defective parvoviruses that readily infect dividing and non-dividing mammalian cells 56 [1] . AAVs can deliver up to 4.5 kilobase pairs (kbp) of genetic material that is often maintained 57 epigenetically and therefore does not cause insertional mutation. In rare cases, the AAV genome 58 is inserted at regions of host chromosomal instability and breakage. The AAV genome consists of 59 a single stranded DNA with self-complementary ends that form high-molecular-weight head-to-60 tail circular concatemers [2] . These concatemeric circles are often maintained in transduced cells 61 for lasting gene expression in vivo [3] . 62 
63
AAVs are promising agents for gene therapy due to their varying capsid tropism, low 64 immunogenicity, and lasting gene expression [1, 4] . In research, they are ideal for functional studies 65 in vivo. The genetic load can accommodate constitutive or inducible promoters to regulate 66 expression of genes of interest in addition to selectable and/or fluorescent markers. Many new 67 techniques such as Cre-recombination-based AAV targeted evolution (CREATE) have given rise 68 to a myriad of AAV capsids to achieve the desired performance and cell/tissue targeting [5] [6] [7] [8] [9] . 69 Biotech manufacturing has responded to the demand for AAVs by increasing quality and quantity 70 of produced AAV vectors while maintaining reasonable cost. 71 72 Currently, there are several platforms used for production and purification of AAVs [10, 11] . 73 Biotech manufacturing and virus core facilities often rely on helper viruses such as adenovirus, 74 herpesvirus, or baculoviruses for en mass delivery of complementary genes for large-scale and 75 cost-efficient AAV production. In traditional approaches, complementary genes are delivered as 4 76 plasmids to eukaryotic cells with a variety of transfection reagents [12, 13] . Human embryonic 77 kidney 293 cells (HEK293 and HEK293T) are a preferred cell line for packaging AAVs since they 78 constitutively express adenovirus E1a/b factors that are needed for packaging, are economical, and 79 efficiently transfected [12] . To produce AAVs, eukaryotic cells are transfected with three 80 plasmids: 1) an AAV transfer vector carrying the gene of interest flanked by Inverted Terminal 81 Repeats (ITRs), 2) Rep/Cap genes, and 3) Helper plasmid delivering VA RNAs, E2A, and 82 E4OEF6 genes [12] . Following transfection, AAVs are collected from the media or cell lysate and 83 subjected to numerous purification steps [13] [14] [15] [16] [17] . Gradient centrifugation with cesium chloride 84 (CsCl) or iodixanol provides flexibility for AAV purification since it can be used to purify different 85 AAV serotypes. However, using gradients to purify AAV is time consuming and requires multiple 86 purification steps to produce high purity AAV. The formed gradients are fractionated and 87 individually evaluated for amount and purity of AAV particles. Moreover, CsCl can exert toxic 88 effects in animals and therefore, dialysis of fractions containing AAV with a physiologically 89 balanced solution is necessary before use in vivo [15, 17, 18] . As expected, AAV particles are lost 90 after each purification step, and therefore, large amounts of starting material are needed to ensure 91 sufficient amount of AAV recovery. Complexity of purification steps and the length of time often 92 prevents small laboratories from preparing their own AAV samples. Therefore, customized AAV 93 preparations are commercially packaged for a significant cost or research in labs with limited 94 budgets is planned based on available AAV stock preparations. 95 96 Here, we describe a method for a small-scale production of AAVs that allows research laboratories 97 to produce purified virus rapidly, efficiently, and economically. Using this method, we compared 98 and analyzed yields for AAV preparations with serotypes 1, 2, 5, 6, 8, and 9. The process 5 99 effectively isolated infectious AAV particles for all serotypes except for serotype 2. Reduced 100 number of steps in the purification process minimized virus particle loss and saved time. This 101 method allows for a simple, rapid, and efficient virus purification from a small number of 102 transduced cells. AAV production and two-step purification 132 For transfections, each 15-cm dish was seeded with HEK293-AAV cells at 6 x 10 6 cells in 20 ml 133 of DMEM with 10% FBS without antibiotics. Cells were incubated at 37ºC in 5% CO 2 for 24 134 hours before transfection. The AAV cis, AAV trans and pHelper plasmids (33.3 ug of each) were 135 added to 2 ml of sterile 150 mM NaCl solution. Polyethylenimine MAX (PEI "MAX", 136 Polysciences, Warrington, PA, USA) stock solution was prepared at 16 mg/ml in sterile water and 137 the pH was adjusted to 4.5 with sodium hydroxide. 12.5 µl of PEI stock was added to the 2 ml 138 plasmid solution and mixed by vortexing. After 10 minutes of incubation at room temperature, 2 139 ml of solution was added dropwise to a 15-cm plate. Cultures were incubated at 37°C in 5% CO2 140 incubator for 24 hours and then the media was changed to 14 ml of fresh serum-free DMEM 141 containing 2 mM L-glutamine, and 1 mM sodium pyruvate. 120 hours post-transfection, 2ml of 142 5M NaCl was added to the plates and incubation was resumed for an additional 2 hours before 143 collecting the culture medium into 50ml conical tubes. Turbonuclease (Eton Bioscience, San 7 144 Diego, CA, USA) was added to the culture supernatant to a final concentration of 50 units/ml and 145 incubated at 37°C for 1 hour. To remove the cellular debris, the collected culture medium was 146 centrifugated at 3,000 x g for 20 minutes at 4°C. After centrifugation, the supernatant was collected 147 and filtered through a 0.45 µm Durapore PVDF filter (EMD Millipore, Billerica, MA, USA). The AAV genome was titered as previously described [17] . Briefly, AAV samples were serially 162 diluted from 10 -2 to 10 -8 -fold, and the standard curve was generated by diluting the AAV plasmid 163 containing the ITR2 sequence (from 10 5 to 32 copies per 5 µl). The Q-PCR was performed using Organotypic mouse brain slice culture and AAV transduction 182 Brain slices were isolated from C57BL/6J mice (postnatal 6-8 days). Mice were humanely and 183 rapidly sacrificed. Brain slices were prepared according to previously described methods [19] [20] [21] . In order to assess the efficiency and yield of the two-step purification protocol, the same AAV 208 transfer vector, pAAV-hSyn-GFP, was packaged and purified using serotypes 1, 2, 5, 6, 8, and 9 209 as described in the Materials and Methods section. The purification steps from seeding the 210 HEK293-AAV cells to aliquoting and freezing the samples were completed in 8 days (Fig. 1) . 211 Total amount of time per day spent on the purification process is significantly less than traditional 212 purification methods since the need for fraction collection, assaying each fraction, and further 10 213 concentration and dialysis to remove chemicals and impurities is eliminated. Polyethylenimine 214 MAX (PEI) was used as an economical and efficient method to transfect and deliver packaging 215 plasmids to HEK293-AAV cells [17] . Other transfection methods, including calcium phosphate 216 precipitation of DNA, can be substituted for PEI transfection. Cells can be grown in attached 217 monolayers, multilayered flasks, or in suspension depending on the preparation size and user 218 preference. PEI offers the versatility of transfection in adherent or cell suspension cultures. Transfected cells were allowed to express AAV packaging genes and incubated at 37 o C for 5 days. 226 Recent studies have shown that extending incubation time from 3 to 5 days after transfection 227 results in release of AAV particles from cells and their accumulation in culture medium [14, 17, 22] . 228 In order to minimize protein content in the cell medium, the media was switched to serum-free 229 medium 24 hours post transfection. Incubation with high salt (500mM) has been shown to increase 230 the release of AAV particles from the cells [17, 23] . Salt's effect on protein-protein interactions is 231 often responsible for increased protein solubility [24] . Mature AAV particles are stable under high 232 salt and in a wide range of pH conditions. Therefore, salt concentration was increased to enhance 233 AAV particle release from cells without damage to the particles. 253 The number of AAV genocopies (GC) and the titer for individual preparations were determined 254 by standard Q-PCR protocols as described in Material and Methods [17] . These titers were 255 originated from small-scale AAV preparations from five or six 15-cm plates (Table 1) . AAV 256 serotypes 1, 5, 8, and 9 yielded titers of greater than 1E+12 genome copies per ml (GC/ml) in 257 volumes greater than 100 L per preparation. Greater than 1500 genome copies were recovered 12 258 per HEK293 cell. AAV serotypes 2 and 6 had low yields in similar volumes. AAV with serotype 259 8 produced the greatest yield of 1.72E+05 genome copies per cell (Table 1) . To test the purity of samples, comparable genome copies of each sample were resolved via SDS-269 PAGE and stained for protein content with silver stain (Fig. 2a ). Similar amounts of virus for 270 AAV1, 5, 8, and 9 (3E+10 to 1E+11 GC), and 2E+9 and 5E+9 GC for AAV2 and 6 (due to low 271 titer and limited volume that could be loaded onto a well) were loaded onto the gel in Fig. 2a . 272 Equal volumes of AAV preparations (3ul of each preparation) were loaded onto the gel in Fig. 2b . Cores and used for packaging AAVs using the two-step purification method. Silver-staining assay 277 is typically used to detect the major AAV capsid proteins VP1, VP2, and VP3; and to compare the 278 ratios of AAV capsid proteins to impurities. The amount of VP1, VP2, and VP3 is also indicative 279 of the amount of AAV particles present in the preparation (Fig. 2b) . The low genome copies of 280 two-step purification for AAVs with serotypes 2 and 6 are evident on the gel in Fig 2b. However, 281 AAV serotypes 1, 5, 8, and 9 had robust VP1, VP2, VP3 presentations. All two-step preparations 282 had comparable purities to purchased commercial AAV preparations ( Fig. 2a ). its commercially purchased equivalent AAV9 from the UPenn Core were imaged using TEM (Fig.   300 3). As shown in the negative stain images, both samples have similarly stained particles and 301 impurities. The purchased AAV9 from UPenn contained more particles and higher titer. Equal amounts of viral preparations were added dropwise on top of cultured brain tissues and 317 monitored for expression of GFP by confocal microscopy. AAV expression was detected one week 318 after infection. AAV preparations for serotypes 1, 5, 6, 8, and 9 transduced mouse neurons 319 effectively (Fig. 4) In this method, cell transfection and recovery of AAV particles from cell media is performed 348 according to standard protocols. The virus is collected from the culture medium that has been 349 incubated for five days as compared to traditional method of collecting AAV particles from freeze- The purified virus stocks using the two-step method may also contain empty AAV viral capsids. 359 The effect of empty capsids on transduction outcome is still unclear. The presence of empty capsids 360 may increase the unwanted immune response; yet, some studies report that the existence of empty 361 capsids is beneficial and increases transduction [28, 29] .
AAV titers and purity
363
The standard purification protocols also rely on collecting AAV fractions from gradients and 364 examination of each individual fraction for quality and quantity. Samples purified using cesium 365 chloride also require an additional dialysis step to remove toxic cesium chloride. In this protocol, 366 no toxic material is introduced into the collected samples and a protein concentrator device is used
